GSK840

Research use only, not for human use.

GSK840 is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds the RIP3 kinase domain (IC50: 0.9 nM), and inhibits kinase activity (IC50: 0.3 nM).

GSK840 is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds the RIP3 kinase domain (IC50: 0.9 nM), and inhibits kinase activity (IC50: 0.3 nM).(In Vitro):In human HT-29 cells, GSK840 (0.01-3 μM) blocked TNF-induced necroptosis in a concentration-dependent manner. GSK840 binded the kinase domain and inhibited kinase activity with high specificity, targeting a broader range of pro-necrotic stimuli.

GSK840 (GSK'840)(0.01-3 μM; 24 hours) blocks TNF-induced necroptosis in a concentration-dependent manner.GSK840 binds the kinase domain and inhibits kinase activity with high specificity, targeting a broader range of pro-necrotic stimuli than can be achieved with RIP1 kinase inhibitors.Cell Viability Assay Cell Line:Human HT-29 cells (TNF 10 ng/ml + zVAD-fmk 20 μM + SMAC007 100 nM)Concentration:0.01-3 μM Incubation Time:24 hours Result:Blocked TNF-induced necroptosis in a concentration-dependent manner.

——

GSK'840

Apoptosis

RIP kinase

——

——

——

2361146-30-5

365.433

C21H23N3O3

>98% (HPLC)

In Vitro:?DMSO : 110 mg/mL (301.02 mM)

CNC(=O)c1ccc2n(cnc2c1)-c1ccc(CC(=O)OC(C)(C)C)cc1

——

(-20℃)

With Ice Pack

≥ 2 years